Choi Euncheol, Kim Jin Hee, Kim Ok Bae, Kim Mi Young, Oh Young Ki, Baek Sung Gyu
Proton Therapy Center, National Cancer Center, Goyang, Korea.
Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Radiat Oncol J. 2016 Jun;34(2):106-12. doi: 10.3857/roj.2015.01585. Epub 2016 Jun 17.
To identify possible predictors of pathologic complete response (pCR) of rectal cancer after preoperative concurrent chemoradiotherapy (CCRT).
We conducted a retrospective review of 53 patients with rectal cancer who underwent preoperative CCRT followed by radical surgery at a single center between January 2007 and December 2012. The median radiotherapy dose to the pelvis was 54.0 Gy (range, 45.0 to 63.0 Gy). Five-fluorouracil-based chemotherapy was administered via continuous infusion with leucovorin.
The pCR rate was 20.8%. The downstaging rate was 66%. In univariate analyses, poor and undifferentiated tumors (p = 0.020) and an interval of ≥7 weeks from finishing CCRT to surgery (p = 0.040) were significantly associated with pCR, while female gender (p = 0.070), initial carcinoembryonic antigen concentration of <5.0 ng/dL (p = 0.100), and clinical stage T2 (p = 0.100) were marginally significant factors. In multivariate analysis, an interval of ≥7 weeks from finishing CCRT to surgery (odds ratio, 0.139; 95% confidence interval, 0.022 to 0.877; p = 0.036) was significantly associated with pCR, while stage T2 (odds ratio, 5.363; 95% confidence interval, 0.963 to 29.877; p = 0.055) was a marginally significant risk factor.
We suggest that the interval from finishing CCRT to surgery is a predictor of pCR after preoperative CCRT in patients with rectal cancer. Stage T2 cancer may also be an important predictive factor. We hope to perform a robust study by collecting data during treatment to obtain more advanced results.
确定术前同步放化疗(CCRT)后直肠癌病理完全缓解(pCR)的可能预测因素。
我们对2007年1月至2012年12月期间在单一中心接受术前CCRT并随后进行根治性手术的53例直肠癌患者进行了回顾性研究。盆腔的中位放疗剂量为54.0 Gy(范围,45.0至63.0 Gy)。基于5-氟尿嘧啶的化疗通过与亚叶酸钙持续输注给药。
pCR率为20.8%。降期率为66%。在单因素分析中,低分化和未分化肿瘤(p = 0.020)以及从完成CCRT到手术的间隔时间≥7周(p = 0.040)与pCR显著相关,而女性(p = 0.070)、初始癌胚抗原浓度<5.0 ng/dL(p = 0.100)和临床分期T2(p = 0.100)是边缘性显著因素。在多因素分析中,从完成CCRT到手术的间隔时间≥7周(比值比,0.139;95%置信区间,0.022至0.877;p = 0.036)与pCR显著相关,而分期T2(比值比,5.363;95%置信区间,0.963至29.877;p = 0.055)是边缘性显著危险因素。
我们认为,从完成CCRT到手术的间隔时间是直肠癌患者术前CCRT后pCR的一个预测因素。T2期癌症也可能是一个重要的预测因素。我们希望通过在治疗期间收集数据进行一项有力的研究,以获得更先进的结果。